The FDA is tracking hundreds of reported adverse events tied to compounded weight-loss medications and unapproved peptide products, according to agency data reported as of the end of May 2026. The agency had received 990 adverse-event reports associated with compounded semaglutide and more than 730 involving compounded tirzepatide.
The FDA says it is seeing problems with some compounded GLP-1 products, including dosing errors, as unapproved peptide products marketed for weight loss, muscle growth, and recovery become more widely available. The figures represent the first comprehensive public accounting of harm reports tied to compounded GLP-1 drugs.
The data arrives at a moment of intensifying regulatory and legal pressure on compounders, telehealth prescribers, and pharmacies distributing unapproved peptide products.
What happened
As of May 31, 2026, the FDA had logged 990 adverse-event reports linked to compounded semaglutide and over 730 reports linked to compounded tirzepatide. The agency identified dosing errors among the problems associated with some compounded GLP-1 products.
The reports come amid a broader expansion of the gray market for compounded GLP-1 drugs and unapproved peptides, which are being marketed for weight loss, muscle growth, and recovery. The FDA’s tally reflects reports submitted to the agency and does not by itself establish causation for every individual case.
Why it matters
The adverse-event count provides a concrete, agency-tracked measure of reported harm associated with compounded GLP-1 products, a market that has grown rapidly through telehealth prescribing and compounding pharmacies.
The data also arrives as the FDA faces pressure from multiple directions. An advisory committee has recommended opening compounding of six unapproved peptides. A federal appeals court ruling has limited large-scale 503B compounding. And state-level enforcement actions against unsafe peptide pharmacies have surged.
Affected groups include consumers using compounded GLP-1 peptides, telehealth platforms prescribing compounded peptides, 503A and 503B compounding pharmacies, state pharmacy boards, and GLP-1 brand manufacturers Eli Lilly and Novo Nordisk.
What to watch next
- Whether the FDA’s adverse-event tally continues to grow as reporting and enforcement activity increase.
- How the advisory committee recommendation on six unapproved peptides affects compounding policy.
- The impact of the federal appeals court ruling on 503B large-scale compounding operations.
- Further state pharmacy board enforcement actions against peptide compounders.
- Responses from telehealth platforms and compounding pharmacies to heightened regulatory scrutiny.
Sources
- WBAY — FDA tracking hundreds of reports tied to compounded weight-loss drugs and unapproved peptides
- NBC Bay Area — Unapproved GLP-1 drugs
Industry information only. Not medical or legal advice.
